-
the combination of MUC4, MUC16 and MUC20 signature is associated with statistically significant reduced overall survival and increased hazard ratio in pancreatic, colon and stomach cancer.
-
MUC20 knockdown suppresses the malignant phenotypes of PDAC cells at least partially through the inhibition of the HGF/MET pathway.
-
High MUC20 expression is associated wit response to chemotherapy in esophageal squamous cell carcinoma.
-
increased gene expression of MUC16 and MUC20 was found in patients with remission ulcerative colitis
-
A combination of MUC13/MUC20 expression was a potential prognostic marker for patients with ESCC, who received neoadjuvant chemotherapy followed by surgery.
-
Results suggest that MUC20 enhances aggressive behaviors of EOC cells by activating integrin beta1 signaling and provide novel insights into the role of MUC20 in ovarian cancer metastasis.
-
MUC20 is a novel transmembrane mucin expressed by the human corneal and conjunctival epithelia, and suggest that differential expression of MUC20 during differentiation has a role in maintaining ocular surface homeostasis.
-
MUC20 is expressed in recurrent colorectal neoplasms and may have a role in poor outcome
-
Results suggest that MUC20 is a novel regulator of the Met signaling cascade which has a role in suppression of the Grb2-Ras pathway.
-
Reflux laryngitis is associated with down-regulation of mucin gene expression.